----item----
version: 1
id: {CDABCD67-65B6-4427-8A60-D720B051BD9A}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/05/20/FDA OKs Boehringers Stiolto Respimat in COPD
parent: {9272B77E-1398-4EF1-A77A-17C397C8C6D1}
name: FDA OKs Boehringers Stiolto Respimat in COPD
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 655a5ae8-246f-4f74-817e-35f2362595c6

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 233

{1D288E18-BAFF-4498-B284-EF9BC8D32E30}|{38CC267C-7BFB-437D-BEA0-27DBA7B77873}|{8B2376D2-D914-41D6-9402-D3CD38CABF23}|{6813DF9C-1DA9-44AE-9B9D-FB83827E8521}|{C547E0DE-05E0-4671-8C7A-37F0D3DF4F0E}|{C73EC67A-5E68-4D6E-8A63-F12AB8D18B20}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 46

FDA OK's Boehringer's Stiolto Respimat in COPD
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 44

FDA OKs Boehringers Stiolto Respimat in COPD
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1186

<p>The FDA has given Boehringer Ingelheim the go-ahead to market Stiolto Respimat (tiotropium bromide and olodaterol) as a long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.</p><p>The drug is a fixed-dose combination of tiotropium and olodaterol &ndash; two agents BI already markets in the US as individual drugs for COPD &ndash; delivered with the company's Respimat inhaler.</p><p>Tiotropium, a long-acting muscarinic antagonist, is sold by BI as <a href="http://www.scripintelligence.com/home/BIs-Spiriva-Respimat-OKd-faces-crowded-COPD-market-354140" target="_new">Spiriva Respimat</a>, which was OK'd by the FDA this past September.</p><p>Tiotropium also is the active ingredient in BI's Spiriva HandiHaler, also a COPD drug.</p><p>Stiolto Respimat's other component, olodaterol, is the active ingredient in BI's COPD drug <a href="http://www.scripintelligence.com/home/Boehringer-scores-COPD-win-for-Striverdi-Respimat-353144" target="_new">Striverdi Respimat</a>, a long-acting beta-agonist, which won approval on 31 July 2014.</p><p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 300

<p>The FDA has given Boehringer Ingelheim the go-ahead to market Stiolto Respimat (tiotropium bromide and olodaterol) as a long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 44

FDA OKs Boehringers Stiolto Respimat in COPD
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150520T130000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150520T130000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150520T130000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028829
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 46

FDA OK's Boehringer's Stiolto Respimat in COPD
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 11

Expert View
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

358512
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042351Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

655a5ae8-246f-4f74-817e-35f2362595c6
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042351Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
